Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1295105.RAckOyQ9kwWn23nV3hawr5CZsHTW5tzVyhB09Db8DSRlU130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1295105.RAckOyQ9kwWn23nV3hawr5CZsHTW5tzVyhB09Db8DSRlU130_assertion type Assertion NP1295105.RAckOyQ9kwWn23nV3hawr5CZsHTW5tzVyhB09Db8DSRlU130_head.
- NP1295105.RAckOyQ9kwWn23nV3hawr5CZsHTW5tzVyhB09Db8DSRlU130_assertion description "[Although clinical trials have been performed with anti IL-5 (mepolizumab) and anti-CD52 (alemtuzumab) antibodies, their therapeutic role in primary eosinophilic diseases and HES has yet to be established.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1295105.RAckOyQ9kwWn23nV3hawr5CZsHTW5tzVyhB09Db8DSRlU130_provenance.
- NP1295105.RAckOyQ9kwWn23nV3hawr5CZsHTW5tzVyhB09Db8DSRlU130_assertion evidence source_evidence_literature NP1295105.RAckOyQ9kwWn23nV3hawr5CZsHTW5tzVyhB09Db8DSRlU130_provenance.
- NP1295105.RAckOyQ9kwWn23nV3hawr5CZsHTW5tzVyhB09Db8DSRlU130_assertion SIO_000772 26486351 NP1295105.RAckOyQ9kwWn23nV3hawr5CZsHTW5tzVyhB09Db8DSRlU130_provenance.
- NP1295105.RAckOyQ9kwWn23nV3hawr5CZsHTW5tzVyhB09Db8DSRlU130_assertion wasDerivedFrom befree-2016 NP1295105.RAckOyQ9kwWn23nV3hawr5CZsHTW5tzVyhB09Db8DSRlU130_provenance.
- NP1295105.RAckOyQ9kwWn23nV3hawr5CZsHTW5tzVyhB09Db8DSRlU130_assertion wasGeneratedBy ECO_0000203 NP1295105.RAckOyQ9kwWn23nV3hawr5CZsHTW5tzVyhB09Db8DSRlU130_provenance.